Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug shows promise for blocking asthma attacks

NCT ID NCT00983658

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a drug called huMAb OX40L in 29 adults with mild allergic asthma. The drug is an antibody designed to block a protein that triggers allergic reactions in the airways. Researchers measured whether it could prevent breathing problems caused by allergens, compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
huMAb OX40L (a lab-made antibody that blocks a protein involved in allergic reactions)
What this could lead to
If it works, this could point toward a new treatment to control asthma attacks triggered by allergens.
What could go wrong
This is a small, early-phase trial with only 29 people. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

29 people

The number who actually took part.

Started

Sep 2009

Finished

Jan 2011

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Weight between 50 and 125 kg * Mild, stable allergic asthma * History of episodic wheeze and shortness of breath * FEV1 at baseline ≥ 70% of the predicted value * For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the study * For men with partners of childbearing potential, willingness to use condoms with spermicide during treatment * Ability to comprehend and follow all required study procedures * Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and pollen) * Positive allergen-induced early and late airway bronchoconstriction Exclusion Criteria: * A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry * Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection * History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc. * Lung disease other than mild allergic asthma * History of heart, lung, kidney, liver, neurologic or chronic infectious disease * Concomitant disease or condition, which could interfere with the conduct of the study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease * History of serious adverse reaction or hypersensitivity to any drug * Pregnancy or lactation or positive serum pregnancy test at screening * Chronic use of any other medication for treatment of allergic lung disease other than short-acting β2-agonists or ipratropium bromide * Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months (5 half-lives of the drug), including omalizumab * Regular use of tobacco products of any kind or within the previous 6 months, or smoking history \> 10 pack-years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.